Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

BCC 2025 | Selecting patients with breast cancer who can avoid axillary surgery

Walter Weber • 13 Mar 2025
BCC 2025
Breast Cancer
INSEMA SENOMAC SOUND

Walter Weber, MD, Basel University Hospital, Basel, Switzerland, comments on the role of the sentinel lymph node biopsy in the upfront surgery setting. Results from the SENOMAC (NCT02240472), INSEMA (NCT02466737), and SOUND (NCT02167490) trials show that sentinel lymph node biopsy can be safely omitted in selected patients with small tumors and negative ultrasound findings. This approach may be reserved for younger patients or those with more aggressive tumor characteristics, such as stage 3 cancer, HER2-positive, or triple negative breast cancer. This interview took place at the 2025 St. Gallen International Breast Cancer Consensus Meeting in Vienna, Austria.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Walter Weber

PREPEC (OPBC-02): pre-pectoral vs sub-pectoral IBBR after mastectomy
0:42
PREPEC (OPBC-02): pre-pectoral vs sub-pectoral IBBR after mastectomy
Walter Weber • 30 May 2026
Evaluating the role of axillary surgery after neoadjuvant chemotherapy
2:12
Evaluating the role of axillary surgery after neoadjuvant chemotherapy
Walter Weber • 13 Mar 2025
Current indications for axillary dissection in breast cancer
1:28
Current indications for axillary dissection in breast cancer
Walter Weber • 13 Mar 2025
St Gallen BCC 2023 highlights
0:43
St Gallen BCC 2023 highlights
Walter Weber • 17 Mar 2023

Related Videos

Phase I trial of neoadjuvant rintatolimod and celecoxib in resectable mCRC
1:20
Phase I trial of neoadjuvant rintatolimod and celecoxib in resectable mCRC
Sarbajit Mukherjee • 1 Jun 2026
CRCI and compromised adjuvant chemotherapy delivery in cancer
5:16
CRCI and compromised adjuvant chemotherapy delivery in cancer
Filippos Koinis • 1 Jun 2026
ASCENT-04: PFS2 with sacituzumab govitecan and pembrolizumab in PD-L1+ mTNBC
1:12
ASCENT-04: PFS2 with sacituzumab govitecan and pembrolizumab in PD-L1+ mTNBC
Kevin Kalinsky • 31 May 2026
Clinical relevance of PFS2 in metastatic triple-negative breast cancer
1:10
Clinical relevance of PFS2 in metastatic triple-negative breast cancer
Kevin Kalinsky • 31 May 2026
The content of VJOncology is intended for healthcare professionals